Share This

Public company info - China NT Pharma Group Co. Ltd. , 01011.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

China NT Pharma Group Co. Ltd., 01011.HK - Company Profile
Chairman Ng Tit
Share Issued (share) 1,905,000,000
Par Currency U.S. Dollar
Par Value 8.0E-8
Industry Medicine
Corporate Profile Business Summary: NT Pharma is a technology-based pharmaceutical company integrated with research and development (“R&D”), manufacturing and sales of its own branded products, with its products covering therapeutic areas including central nervous system (“CNS”), orthopedics, oncology and hematology. NT Pharma owns two National Class 1 new drugs, one well-known international innovative brand-name drug, and a number of generic drugs; it conducts its manufacturing through three subsidiaries, namely Suzhou First Pharmaceutical Co., Ltd. (“Suzhou First”), NT Biopharmaceuticals Jiangsu Co., Ltd. (“Jiangsu Biopharma”) and NT Pharma (Changsha) Co., Ltd. (“Changsha Pharma”); and owns several sales and distribution companies with professional sales and R&D specialists. It also has an extensive sales network in China, covering nearly 10,000 hospitals. Performance for the year: The overall revenue of the Group from continuing operations for the year ended 31 December 2020 (the “Year under Review”) increased by RMB68.2 million to RMB221.7 million, as compared with RMB153.5 million for the corresponding period in 2019. Operating loss from continuing operations for the year ended 31 December 2020 decreased by RMB137 million to RMB113.8 million, as compared with an operating loss of RMB250.8 million for the corresponding period in 2019. The Group recorded a loss of RMB191.3 million for the year ended 31 December 2020, as compared with a loss of RMB355.1 million for the corresponding period in 2019, representing a decrease of 46.1% year on year. Business Review In the year of 2020, the outbreak of novel coronavirus pneumonia (“COVID-19”) epidemic had a significant impact on the economy, and the Chinese government implemented strict pandemic prevention and control measures to contain the spread of the disease, with the pharmaceutical industry being more affected from March 2020 to May 2020, as outpatient and ward numbers fell sharply, resulting in a sudden drop in sales. Despite the tremendous downward pressure on China’s economic growth, the pharmaceutical industry was able to maintain its growth momentum under the guidance of the Outline of the 14th Five-Year Plan for the National Economic and Social Development of the PRC “The Fourteen FiveYear Plan” (2021-2025) and the “Healthy China 2030” Planning Outline, and the benefits of growing market demand and the government’s increased investment in the pharmaceutical industry, which is evolving in the direction of high-quality and innovation-driven development. Following last year’s major institutional reform to streamline the regulatory framework for drugs, the Chinese government has intensified its reform efforts by amending the Drug Administration Law, effective from 1 December 2019, with the aim of improving health legislation, strengthening drug administration and increasing penalties for non-compliance. The legislative reform and the continuous introduction of extended policies, including the promotion of consistency evaluation on quality and generic drugs, the adjustment of the reimbursement drug catalogue, the release of a major drug-monitoring list and the expansion of the centralised drug procurement program to more provinces and cities, have posed significant opportunities and challenges to the pharmaceutical market and the Group. Challenging economic conditions and the accelerated implementation of regulatory changes have further intensified competition in all aspects of the pharmaceutical industry, putting tremendous pressure on the Group’s results. For the Year under Review, the revenue of the Group was RMB221.7 million, representing an increase of 44.4% as compared to RMB153.5 million recorded for the corresponding period in 2019. The increase was mainly attributable to: (i) the change in industry policies, change in sales model and price; (ii) the sales hindered by the outbreak of COVID-19 epidemic; and (iii) a change in sales volume of Songzhi Wan due to the lack of ability to intensify the marketing efforts under the context of tight resources. Area of CNS Shusi (generic name: quetiapine fumarate tablets) is the Group’s major product in the area of CNS. It is the first proprietary product which is researched and developed, manufactured and sold by the Group. Shusi is mainly used for the treatment of schizophrenia and maniacal is insult us as a result of bipolar affective disorder, which is an atypical antipsychotic firsttier drug. Shusi has been in the market for more than 15 years since its debut in 2003. It has developed a strong brand image which is widely recognised by clinical practitioners and the market. During the Period Under Review, the Group has completed all the tasks involving consistency evaluations in pharmaceutical development, production transfers and clinical bioequivalence. On 2 January 2020, the Group received a certification of consistency evaluation for the generic drug quetiapine fumarate tablets (Shusi) from the National Medical Products Administration. The completion of the consistency evaluation does not only represent the recognition of Shusi’s drug quality and therapeutic effect, but also facilitates the acceptance of Shusi in the field of clinical psychiatry, posing a positive effect on expanding the market share of quetiapine. Prospects: In the face of the global economic slowdown and domestic headwinds, the Chinese government has introduced strong fiscal and monetary policies to support businesses, stimulate domestic demand and maintain employment in order to tide over the difficult times. Although China’s growth rate is slowing down, the government is expected to continue to invest in healthcare reform in “The Fourteen Five-Year Plan”. Despite the implementation of a series of regulatory reforms to rationalize drug prices, improve access to new drugs, stricter control over drug quality and safety, promote innovation and enhance market competition, the Group remains optimistic about the tremendous opportunities in the pharmaceutical market as demand will continue to increase due to the rapidly aging population, increasing living standards and rising health awareness as a result of recent COVID-19 epidemic outbreaks. Going forward, the economic and operating environment is expected to be more complex and volatile. The outbreak of COVID-19 epidemic and the sweeping changes in the regulatory landscape of the industry have caused disruptions to the market and the entire industry chain, thus posing significant challenges to the production and operations of the Group’s business segments operating in the PRC. As the positive progress of the Group’s manufacturing segment reflects the effectiveness of the strategic initiatives taken, the management is committed to pursuing these strategic initiatives and believes that the Group will lay a stronger foundation for sustainable growth in revenue and profitability in the long run. In view of the uncertainty of the breadth and depth of the impact of the COVID-19 epidemic on the global and PRC economies, the management will continue to strive to adopt flexible strategies to respond to market changes and remain vigilant in controlling operating costs in order to enhance operational efficiency and maintain the Group’s financial flexibility. With the Group’s improving financial position, the Group believes that it is capable to cope with unexpected events and challenges and maintain its development path for a bright future.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.